# FDA 483 - Vetter Pharma Fertigung GmbH & Co. KG (Ravensburg Mooswiesen) - March 19, 2024

Source: https://www.globalkeysolutions.net/records/483/vetter-pharma-fertigung-gmbh-co-kg-ravensburg-mooswiesen/e6b0aa44-ffb1-43ad-8bfa-ed4a14f0dd72

> FDA 483 for Vetter Pharma Fertigung GmbH & Co. KG (Ravensburg Mooswiesen) on March 19, 2024. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Vetter Pharma Fertigung GmbH & Co. KG (Ravensburg Mooswiesen)
- Inspection Date: 2024-03-19
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Documents

- [483 - Unknown Date](https://www.globalkeysolutions.net/records/483/vetter-pharma-fertigung-gmbh-co-kg-ravensburg-mooswiesen/e00b7a6f-272d-4773-a287-89a5ec741892)
- [483 - 2022-08-26](https://www.globalkeysolutions.net/records/483/vetter-pharma-fertigung-gmbh-co-kg-ravensburg-mooswiesen/b7363b3b-9f74-4b28-beed-5e9a49563aa1)
- [483 - 2018-02-09](https://www.globalkeysolutions.net/records/483/vetter-pharma-fertigung-gmbh-co-kg-ravensburg-mooswiesen/d2c2a04a-70fd-47d0-9898-d4c6ae6f5b44)
- [483 - 2022-08-26](https://www.globalkeysolutions.net/records/483/vetter-pharma-fertigung-gmbh-co-kg-ravensburg-mooswiesen/4ec9333d-9e7c-41d0-97ba-d92766818280)
- [483 - 2022-08-26](https://www.globalkeysolutions.net/records/483/vetter-pharma-fertigung-gmbh-co-kg-ravensburg-mooswiesen/0ec75ad9-5019-4fcb-b904-0d3d4af3f325)

## Related Officers

- [Lead  Biologist](https://www.globalkeysolutions.net/people/leiyun-boone/454ce531-ae82-4ae4-9b3d-8e4e8afed127)
- [Bo Chi](https://www.globalkeysolutions.net/people/bo-chi/9c83477d-58c1-4183-832e-ce8cbd25a521)
- [Olumide A. Martins](https://www.globalkeysolutions.net/people/olumide-a-martins/e325adf8-64a0-426a-b22f-2503e41a3f5a)

Company: https://www.globalkeysolutions.net/companies/vetter-pharma-fertigung-gmbh-co-kg-ravensburg-mooswiesen/d0287c3d-c544-40de-aece-ba713025286c

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd